SG11201505227YA - A method for predicting the risk of getting cancer or diagnosing cancer in a subject - Google Patents
A method for predicting the risk of getting cancer or diagnosing cancer in a subjectInfo
- Publication number
- SG11201505227YA SG11201505227YA SG11201505227YA SG11201505227YA SG11201505227YA SG 11201505227Y A SG11201505227Y A SG 11201505227YA SG 11201505227Y A SG11201505227Y A SG 11201505227YA SG 11201505227Y A SG11201505227Y A SG 11201505227YA SG 11201505227Y A SG11201505227Y A SG 11201505227YA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- predicting
- risk
- subject
- getting
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/665—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- G01N2333/70—Enkephalins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13150564 | 2013-01-08 | ||
| PCT/EP2014/050144 WO2014108397A1 (en) | 2013-01-08 | 2014-01-07 | A method for predicting the risk of getting cancer or diagnosing cancer in a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201505227YA true SG11201505227YA (en) | 2015-08-28 |
Family
ID=47469833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201505227YA SG11201505227YA (en) | 2013-01-08 | 2014-01-07 | A method for predicting the risk of getting cancer or diagnosing cancer in a subject |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10605812B2 (en) |
| EP (1) | EP2943792B1 (en) |
| JP (1) | JP6317763B2 (en) |
| CN (2) | CN104937419B (en) |
| CA (1) | CA2897245A1 (en) |
| ES (1) | ES2710974T3 (en) |
| HK (1) | HK1215301A1 (en) |
| RU (1) | RU2701730C2 (en) |
| SG (1) | SG11201505227YA (en) |
| TR (1) | TR201901828T4 (en) |
| WO (1) | WO2014108397A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018276361A1 (en) * | 2017-05-30 | 2019-12-05 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction |
| WO2018225830A1 (en) * | 2017-06-08 | 2018-12-13 | 国立大学法人宮崎大学 | Lung cancer detection method |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8613431D0 (en) * | 1986-06-03 | 1986-07-09 | Medical Res Council | Human tachykinins |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5430047A (en) * | 1994-04-07 | 1995-07-04 | Warner-Lambert Company | Neurotensin antagonists |
| CN1311208A (en) * | 2000-03-02 | 2001-09-05 | 上海博德基因开发有限公司 | New polypeptide-human beta-pre-protachy kinin 9 and polynucleotide for coding said polypeptide |
| CA2473128A1 (en) * | 2002-01-31 | 2003-08-07 | F. Hoffmann-La Roche Ag | Genetic polymorphisms in the preprotachykinin gene |
| US7485298B2 (en) * | 2002-05-23 | 2009-02-03 | Michael Powell | Diagnosis and treatment of human dormancy-related sequellae |
| US20050186577A1 (en) * | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| ES2471403T3 (en) * | 2004-04-20 | 2014-06-26 | Sphingotec Gmbh | Use of tachykinin precursors and / or their fragments in medical diagnosis |
| US8013123B2 (en) * | 2004-05-13 | 2011-09-06 | B.R.A.H.M.S. Gmbh | Use of precursors of enkephalins and/or their fragments in medical diagnostics |
| DE102005003687A1 (en) * | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunodiagnostic determination of neurotensin in mammal blood, comprises injecting immune active N-terminal mammal proneurotensin in to the serum- or plasma- sample |
| JP5298266B2 (en) * | 2006-03-31 | 2013-09-25 | 静岡県 | Evaluation kit for small cell lung cancer |
| EP2637020A3 (en) * | 2007-06-29 | 2014-01-08 | Correlogic Systems Inc. | Predictive markers for ovarian cancer |
| WO2009044561A1 (en) * | 2007-10-03 | 2009-04-09 | Shizuoka Prefecture | ANTI-proNT/NMN MONOCLONAL ANTIBODY |
| US20100304992A1 (en) * | 2007-11-30 | 2010-12-02 | Genomictree, Inc. | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene |
| ES2624261T3 (en) * | 2008-09-05 | 2017-07-13 | A & G Pharmaceutical, Inc. | Procedures for diagnosing cancer and determining overall survival and disease-free survival of cancer patients |
| DK2427764T3 (en) * | 2009-05-05 | 2017-09-11 | Brahms Gmbh | VASOACTIVE HORMON-BASED STRATIFICATION OF PATIENTS SUFFERING OF DISEASES RELATED TO ENDOTELIAL FUNCTION / DYSFUNCTION |
| CN102573875A (en) * | 2009-08-14 | 2012-07-11 | 阿勒根公司 | Methods of treating cancer using tachykinin retargeted endopeptidases |
| CN102139107B (en) * | 2011-03-23 | 2012-10-03 | 浙江理工大学 | Anticancer effect of antagonist of neurokinin receptor |
| EP2533052A1 (en) * | 2011-06-07 | 2012-12-12 | B.R.A.H.M.S GmbH | Diagnostic use of proSomatostatin |
| ES2676737T3 (en) * | 2012-10-02 | 2018-07-24 | Sphingotec Gmbh | Method to predict the risk of getting cancer or to diagnose cancer in a female subject |
-
2014
- 2014-01-07 CA CA2897245A patent/CA2897245A1/en not_active Abandoned
- 2014-01-07 US US14/759,724 patent/US10605812B2/en active Active
- 2014-01-07 SG SG11201505227YA patent/SG11201505227YA/en unknown
- 2014-01-07 WO PCT/EP2014/050144 patent/WO2014108397A1/en active Application Filing
- 2014-01-07 TR TR2019/01828T patent/TR201901828T4/en unknown
- 2014-01-07 RU RU2015133019A patent/RU2701730C2/en active
- 2014-01-07 CN CN201480004101.4A patent/CN104937419B/en active Active
- 2014-01-07 ES ES14700091T patent/ES2710974T3/en active Active
- 2014-01-07 CN CN201810791338.1A patent/CN109116025A/en active Pending
- 2014-01-07 EP EP14700091.3A patent/EP2943792B1/en active Active
- 2014-01-07 JP JP2015551195A patent/JP6317763B2/en active Active
-
2016
- 2016-03-21 HK HK16103236.0A patent/HK1215301A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10605812B2 (en) | 2020-03-31 |
| WO2014108397A1 (en) | 2014-07-17 |
| TR201901828T4 (en) | 2019-03-21 |
| US20150346207A1 (en) | 2015-12-03 |
| CN109116025A (en) | 2019-01-01 |
| CN104937419B (en) | 2018-08-10 |
| JP2016505137A (en) | 2016-02-18 |
| CA2897245A1 (en) | 2014-07-17 |
| RU2015133019A (en) | 2017-02-15 |
| ES2710974T3 (en) | 2019-04-29 |
| RU2701730C2 (en) | 2019-10-01 |
| WO2014108397A4 (en) | 2014-10-02 |
| EP2943792A1 (en) | 2015-11-18 |
| CN104937419A (en) | 2015-09-23 |
| EP2943792B1 (en) | 2018-11-14 |
| JP6317763B2 (en) | 2018-04-25 |
| HK1215301A1 (en) | 2016-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1226484A1 (en) | A method for predicting the risk of getting a major adverse cardiac event | |
| PT2976013T (en) | Methods for assessing erythema | |
| EP2962268A4 (en) | Systems and methods for improving clinical documentation | |
| EP2972308A4 (en) | Biomarkers and methods for predicting preterm birth | |
| HK1211719A1 (en) | Customer-data analysis evaluation system | |
| EP2972393A4 (en) | Biomarkers and methods for predicting preeclampsia | |
| LU92173B1 (en) | Distance determination method | |
| HK1209799A1 (en) | A non-invasion cancer detection method and a kit for performing the same | |
| EP3004334A4 (en) | Method of assessing risk of pml | |
| GB201516410D0 (en) | Tool for measuring wellbore geometry | |
| SG11201601288RA (en) | Integrated hydrocarbon analysis | |
| ZA201600963B (en) | Methods and kits for predicting the risk of having a cardiovascular disease or event | |
| HK1216779A1 (en) | Predictive biomarker for cancer therapy | |
| IL244632A0 (en) | Cancer biomarker and diagnostic | |
| GB201315024D0 (en) | Lubricant analysis | |
| GB201304507D0 (en) | Ultrasonic Inspection Method | |
| HK1212762A1 (en) | A method for predicting the risk of getting cancer or diagnosing cancer in a female subject | |
| EP2948769A4 (en) | Platelet biomarkers in cancer diagnosis | |
| GB2535065B (en) | Method for preprocessing metallic magnesium | |
| EP2948903A4 (en) | Asset-driven workflow modeling | |
| HK1215301A1 (en) | A method for predicting the risk of getting cancer or diagnosing cancer in a subject | |
| PT2821771T (en) | Testing method | |
| GB201307256D0 (en) | Diagnostic method | |
| GB201316752D0 (en) | Methods for determining temperature or temperature | |
| GB201302036D0 (en) | Diagnosis |